Previous studies have shown that AI can be used to detect liver fibrosis and diagnose non-alcoholic fatty liver disease (NAFLD). It can also help differentiate focal liver lesions, diagnose ...
Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024Iqirvo approved for use in the U.S. in June 2024, in the E.U. in September 202 ...